12:00 AM
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Esbriet pirfenidone regulatory update

The U.K.'s NICE issued draft guidance recommending against Esbriet pirfenidone from InterMune to treat mild to moderate idiopathic pulmonary fibrosis (IPF). The committee said Esbriet had a "modest but measurable effect" on slowing decline in lung function, but said there are "uncertainties" over the drug's long-term clinical benefit and...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >